◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › ALKS

Alkermes Plc (ALKS) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-08-02

Alkermes Plc (ALKS) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Dublin, Ireland with about 2,050 employees. Its market capitalization is roughly $7 billion. In the fiscal year ended 2025-12-31, ALKS reported $1.5B in revenue and $242M in net income.

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.

Interactive charts & full statements → Open the ALKS valuation workbench →

ALKS Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$1.7B	$1.5B	$1.6B	$1.7B	$1.1B	$1.2B	$1.0B	$1.2B	$1.1B	$903M	$746M	$628M	$619M	$433M	$576M	$576M	$390M	$187M	$178M	$327M	$241M
Gross Profit	$1.4B	$1.3B	$1.3B	$1.4B	$894M	$976M	$860M	$991M	$918M	$749M	$614M	$489M	$443M	$299M	$265M	$405M	$262M	$134M	$129M	$283M	$200M
Gross Margin %	84.6%	86.7%	84.2%	84.8%	80.4%	83.2%	82.8%	84.6%	83.9%	82.9%	82.3%	77.9%	71.6%	69.0%	46.1%	70.4%	67.3%	72.0%	72.3%	86.7%	83.1%
Operating Income (EBIT)	$117M	$254M	$421M	$414M	($6M)	$98M	($112M)	($175M)	($99M)	($148M)	($209M)	($224M)	($87M)	$16M	$82M	$82M	($88M)	($46M)	($43M)	$135M	($3M)
Operating Margin %	7.0%	17.2%	27.0%	24.9%	-0.5%	8.3%	-10.8%	-15.0%	-9.1%	-16.4%	-28.0%	-35.7%	-14.1%	3.6%	14.2%	14.2%	-22.6%	-24.4%	-24.1%	41.3%	-1.2%
Net Income	$66M	$242M	$367M	$356M	($158M)	($48M)	($111M)	($197M)	($139M)	($158M)	($208M)	($227M)	($30M)	$18M	$25M	$25M	($114M)	($46M)	($40M)	$131M	$167M
Net Margin %	4.0%	16.4%	23.6%	21.4%	-14.2%	-4.1%	-10.7%	-16.8%	-12.7%	-17.5%	-28.0%	-36.1%	-4.9%	4.1%	4.3%	4.3%	-29.1%	-24.4%	-22.2%	39.9%	69.4%
EBITDA	$218M	$331M	$495M	$519M	$60M	$178M	($6M)	($103M)	($8M)	($33M)	($105M)	($125M)	$97M	$66M	$115M	$158M	($38M)	($35M)	($14M)	$155M	$16M
Earnings Per Share (EPS)	$0.39	$1.43	$2.17	$2.10	$-0.97	$-0.30	$-0.70	$-1.25	$-0.90	$-1.03	$-1.38	$-1.52	$-0.21	$0.12	$0.18	$0.18	$-1.19	$-0.48	$-0.42	$1.36	$1.62
Shares Outstanding (M)	167M	169M	169M	170M	164M	161M	159M	157M	155M	153M	151M	149M	145M	145M	137M	137M	96M	96M	95M	96M	103M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALKS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$496M	$393M	$385M	$394M	$391M	$307M	$430M	$378M
Gross Profit	$398M	$331M	$338M	$343M	$341M	$257M	$368M	$315M
Gross Margin %	80.2%	84.3%	88.0%	86.9%	87.3%	84.0%	85.5%	83.3%
Operating Income (EBIT)	$18M	($48M)	$58M	$89M	$93M	$14M	$163M	$105M
Operating Margin %	3.7%	-12.3%	15.1%	22.6%	23.8%	4.5%	37.8%	27.7%
Net Income	$1M	($66M)	$49M	$83M	$87M	$22M	$147M	$92M
Net Margin %	0.1%	-16.9%	12.8%	21.0%	22.3%	7.3%	34.1%	24.4%
EBITDA	$54M	($22M)	$76M	$109M	$113M	$33M	$181M	$123M
Earnings Per Share (EPS)	$0.00	$-0.40	$0.29	$0.49	$0.52	$0.13	$0.88	$0.55
Shares Outstanding (M)	167M	166M	169M	169M	168M	169M	167M	167M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALKS Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$251M	$521M	$439M	$401M	$21M	$102M	$83M	$72M	$99M	$19M	($64M)	($40M)	$11M	$92M	$127M	($2M)	($6M)	($12M)	$35M	$42M	$84M
Capital Expenditures (CapEx)	$30M	$40M	$33M	$48M	$38M	$29M	$42M	$91M	$69M	$51M	$44M	$53M	$34M	$19M	$22M	$17M	$9M	$16M	$6M	$22M	$36M
Free Cash Flow (FCF)	$222M	$480M	$406M	$353M	($17M)	$73M	$41M	($19M)	$30M	($32M)	($107M)	($93M)	($23M)	$73M	$104M	($19M)	($15M)	($28M)	$29M	$21M	$47M
FCF Margin %	13.3%	32.6%	26.0%	21.2%	-1.6%	6.2%	3.9%	-1.6%	2.7%	-3.5%	-14.4%	-14.8%	-3.6%	16.9%	18.1%	-3.4%	-3.9%	-15.0%	16.3%	6.3%	19.7%
Dividends Paid	—	—	—	—	$1M	$9M	$1M	$10M	—	$0M	$0M	$0M	$0M	—	$0M	$0M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALKS Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$145M	($166M)	$170M	$102M	$150M	$99M	$190M	$82M
Capital Expenditures (CapEx)	$8M	$4M	$0M	$17M	$13M	$10M	$10M	$8M
Free Cash Flow (FCF)	$137M	($170M)	$170M	$84M	$137M	$89M	$181M	$73M
FCF Margin %	27.6%	-43.2%	44.2%	21.4%	35.1%	28.9%	42.0%	19.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALKS Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$4.4B	$2.5B	$2.1B	$2.1B	$2.0B	$2.0B	$1.9B	$1.8B	$1.8B	$1.8B	$1.7B	$1.9B	$1.9B	$1.6B	$1.5B	$1.4B	$452M	$516M	$520M	$656M	$730M
Cash & Cash Equivalents	$512M	$1.1B	$291M	$457M	$292M	$338M	$273M	$204M	$267M	$191M	$186M	$181M	$224M	$168M	$97M	$84M	$38M	$79M	$74M	$101M	$321M
Total Liabilities	$2.6B	$711M	$591M	$934M	$920M	$912M	$883M	$720M	$654M	$594M	$517M	$541M	$524M	$512M	$518M	$581M	$60M	$103M	$101M	$351M	$346M
Total Debt (Short + Long-Term)	$34M	$7M	$6M	$296M	$303M	$312M	$291M	$286M	$279M	$281M	$284M	$350M	$358M	$722M	$403M	$451M	$12M	$51M	$76M	$186M	$158M
Total Shareholders' Equity	$1.8B	$1.8B	$1.5B	$1.2B	$1.0B	$1.1B	$1.1B	$1.1B	$1.2B	$1.2B	$1.2B	$1.3B	$1.4B	$1.1B	$952M	$854M	$392M	$413M	$419M	$305M	$385M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ALKS viewer.

ALKS Metric Deep Dives

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

UTHR · United Therapeutics Corporation — $21 billion
NBIX · Neurocrine Biosciences Inc — $15 billion
ELAN · Elanco Animal Health — $11 billion
RDY · Dr. Reddy’s Laboratories Ltd ADR — $10 billion
LNTH · Lantheus Holdings Inc — $7 billion
HIMS · Hims Hers Health Inc — $7 billion
AMRX · Amneal Pharmaceuticals, Inc. Class A Common Stock — $7 billion
KNSA · Kiniksa Pharmaceuticals Ltd — $6 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← ALKEM All “A” companies ALKT →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.